STAT December 16, 2025
Michael Kinch, Kevin Gardner

U.S. biopharma is now a Ford Mustang racing against the Chinese-built BYD Yangwang U9 supercar

This essay is part of a First Opinion series on the future of the National Institutes of Health and American science.

Around the world, nations with robust research and development infrastructure race to create therapeutics that meet the needs of their residents. Simply put, they dictate research priorities based on need. During the Covid pandemic, the United States was one of the first countries to gain access to vaccines to protect its citizens.

Beyond the public health benefits, pharmaceutical pipelines are powerful economic drivers that fuel entire industries and are underpinned by research enterprises consisting of both public and private sector scientists, who generate the...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech
What’s new with GLP-1s
Navigating the Shift: 2026 Medicare Drug Pricing and the Future of Pharmacy
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model

Share Article